Publication | Open Access

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

Mutant P53 DegradationMutant P53-mediated AngiogenesisAngiogenesisMedicineVascular BiologyAnti-cancer AgentTumor SuppressorPharmacologyCell BiologyCancer ResearchNovel TherapyTumor Biology